S&P 500 falls as traders turn sour on tech
Investing.com - H.C. Wainwright has assumed coverage on Dyadic International (NASDAQ:DYAI) with a Buy rating and a $3.00 price target, according to a research note released Thursday. According to InvestingPro data, analysts’ price targets for the stock range from $5 to $9, suggesting significant upside potential from the current price of $1.1.
The firm cited Dyadic’s strategic shift from research and development to a commercial focus as a key factor in its positive outlook. H.C. Wainwright analyst Swayampakula Ramakanth noted that the biotechnology company, which produces recombinant proteins using proprietary fungus-based platforms, has established three key partnerships expected to generate revenue beginning in 2026. The company has already demonstrated strong revenue growth, with InvestingPro data showing a 129.2% increase in the last twelve months, though it remains unprofitable.
These partnerships include recombinant human serum albumin with Proliant Health and Biologicals, a cellulosic enzyme cocktail called EN3ZYME with Fermbox Bio, and a non-animal dairy enzyme with Inzymes ApS. All three products are expected to contribute to Dyadic’s topline starting next year.
The company has historically generated revenue by conducting R&D services for third-party collaborators and sublicensees since selling its industrial enzymes business in 2015. Dyadic’s technology is based on the thermophilic filamentous fungus Thermothelomyces heterothallica C1.
H.C. Wainwright also expressed optimism about Dyadic’s ongoing pharmaceutical collaborations through grant funding and its plans to expand its platform into additional non-pharmaceutical applications, which the firm views as potential upside to current estimates. With the next earnings report due on November 5th, investors can access comprehensive analysis and additional insights through the detailed Pro Research Report available on InvestingPro, which covers over 1,400 US stocks including Dyadic International .
In other recent news, Dyadic International has reported significant developments that may interest investors. The company posted its financial results for the second quarter of 2025, showing revenue of $967,000, which slightly exceeded expectations, although it continues to experience a net loss with an EPS of -0.06, matching forecasts. Dyadic also announced milestone payments achieved through its partnerships, receiving $250,000 from Inzymes for improvements in non-animal dairy enzymes and expecting a $500,000 payment from Proliant for recombinant human albumin productivity. Additionally, Craig-Hallum has initiated coverage of Dyadic International with a Buy rating and a price target of $5.00. The research firm highlighted Dyadic’s strategic shift towards commercializing its C1-cell protein production platform and Dapibus platforms. These recent developments underscore Dyadic’s transition towards commercial operations after decades of focusing on research and development.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.